Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Change in Receivables (2016 - 2025)

Cytosorbents (CTSO) has disclosed Change in Receivables for 14 consecutive years, with -$303000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 77.1% year-over-year to -$303000.0, compared with a TTM value of $531419.0 through Sep 2025, up 95.86%, and an annual FY2024 reading of $1.7 million, up 600.45% over the prior year.
  • Change in Receivables was -$303000.0 for Q3 2025 at Cytosorbents, up from -$336889.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $1.4 million in Q2 2023 and bottomed at -$1.3 million in Q3 2024.
  • Average Change in Receivables over 5 years is $119677.8, with a median of $28046.0 recorded in 2021.
  • The sharpest move saw Change in Receivables soared 752.71% in 2022, then plummeted 701.71% in 2023.
  • Year by year, Change in Receivables stood at -$698683.0 in 2021, then skyrocketed by 161.32% to $428400.0 in 2022, then crashed by 183.49% to -$357670.0 in 2023, then surged by 405.15% to $1.1 million in 2024, then tumbled by 127.76% to -$303000.0 in 2025.
  • Business Quant data shows Change in Receivables for CTSO at -$303000.0 in Q3 2025, -$336889.0 in Q2 2025, and $79889.0 in Q1 2025.